Items Tagged ‘COMFORT 1’

June 20th, 2017

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia

By

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers, which together are the third leading cause of cancer deaths in the U.S.; AML is responsible for more […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, AML, asco, blood cancer, COMFORT 1, Enasidenib, IDH2 gene, jakafi, Leukemia, myelofibrosis, News


June 7th, 2016

Jakafi Significantly Improves Long-Term Outcomes in Myelofibrosis

By

The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Myelofibrosis (MF) is a type of blood cancer known as a myeloproliferative neoplasm that is chronic and progressive in nature. It involves the […]

View full entry

Tags: 2016, asco, blood cancer, COMFORT 1, jakafi, myelofibrosis, Myeloproliferative Neoplasms MPN, News